[go: up one dir, main page]

MXPA05011411A - 1,4-diazepinas sustituidas y usos de las mismas. - Google Patents

1,4-diazepinas sustituidas y usos de las mismas.

Info

Publication number
MXPA05011411A
MXPA05011411A MXPA05011411A MXPA05011411A MXPA05011411A MX PA05011411 A MXPA05011411 A MX PA05011411A MX PA05011411 A MXPA05011411 A MX PA05011411A MX PA05011411 A MXPA05011411 A MX PA05011411A MX PA05011411 A MXPA05011411 A MX PA05011411A
Authority
MX
Mexico
Prior art keywords
diazepines
substituted
hdm2
solvate
hydrate
Prior art date
Application number
MXPA05011411A
Other languages
English (en)
Inventor
Kristi Leonard
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MXPA05011411A publication Critical patent/MXPA05011411A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L45/00—Routing or path finding of packets in data switching networks
    • H04L45/02—Topology update or discovery
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L45/00—Routing or path finding of packets in data switching networks
    • H04L45/24—Multipath
    • H04L45/245—Link aggregation, e.g. trunking
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L45/00—Routing or path finding of packets in data switching networks
    • H04L45/50—Routing or path finding of packets in data switching networks using label swapping, e.g. multi-protocol label switch [MPLS]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L47/00—Traffic control in data switching networks
    • H04L47/50—Queue scheduling
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02D—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN INFORMATION AND COMMUNICATION TECHNOLOGIES [ICT], I.E. INFORMATION AND COMMUNICATION TECHNOLOGIES AIMING AT THE REDUCTION OF THEIR OWN ENERGY USE
    • Y02D30/00—Reducing energy consumption in communication networks
    • Y02D30/50—Reducing energy consumption in communication networks in wire-line communication networks, e.g. low power modes or reduced link rate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Signal Processing (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Data Exchanges In Wide-Area Networks (AREA)

Abstract

La presente invencion esta dirigida a 1,4-diazepinas novedosas composiciones farmaceuticas de las mismas y el uso de las mismas como inhibidores de interacciones de HDM2-p53; los compuestos tienen la formula I como se define aqui, con R1 a R8 y X como se define aqui o un solvato, hidrato o sal farmaceuticamente aceptable de los mismos.
MXPA05011411A 2003-04-25 2004-04-21 1,4-diazepinas sustituidas y usos de las mismas. MXPA05011411A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46526503P 2003-04-25 2003-04-25
PCT/US2004/012240 WO2004096134A2 (en) 2003-04-25 2004-04-21 Substituted 1,4-diazepines and uses thereof

Publications (1)

Publication Number Publication Date
MXPA05011411A true MXPA05011411A (es) 2006-05-31

Family

ID=33418213

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011411A MXPA05011411A (es) 2003-04-25 2004-04-21 1,4-diazepinas sustituidas y usos de las mismas.

Country Status (14)

Country Link
US (1) US20040213264A1 (es)
EP (1) EP1617807A4 (es)
JP (1) JP2007525457A (es)
KR (1) KR20060007035A (es)
CN (1) CN1809362A (es)
AU (1) AU2004233833A1 (es)
BR (1) BRPI0409641A (es)
CA (1) CA2523561A1 (es)
CO (1) CO5700770A2 (es)
HR (1) HRP20050919A2 (es)
IS (1) IS8074A (es)
MX (1) MXPA05011411A (es)
NO (1) NO20055568L (es)
WO (1) WO2004096134A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050227932A1 (en) * 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US7085574B2 (en) * 2003-04-15 2006-08-01 Qualcomm, Incorporated Grant channel assignment
US7386630B2 (en) * 2003-04-30 2008-06-10 Nokia Corporation Using policy-based management to support Diffserv over MPLS network
AT501480B8 (de) * 2004-09-15 2007-02-15 Tttech Computertechnik Ag Verfahren zum erstellen von kommunikationsplänen für ein verteiltes echtzeit-computersystem
CN100334857C (zh) * 2004-09-27 2007-08-29 华为技术有限公司 一种环网及其业务实现方法
US7453804B1 (en) * 2005-02-08 2008-11-18 Packeteer, Inc. Aggregate network resource utilization control scheme
US20060187828A1 (en) * 2005-02-18 2006-08-24 Broadcom Corporation Packet identifier for use in a network device
US7936770B1 (en) * 2005-03-08 2011-05-03 Enterasys Networks, Inc. Method and apparatus of virtual class of service and logical queue representation through network traffic distribution over multiple port interfaces
US9608929B2 (en) * 2005-03-22 2017-03-28 Live Nation Entertainment, Inc. System and method for dynamic queue management using queue protocols
US7889711B1 (en) 2005-07-29 2011-02-15 Juniper Networks, Inc. Filtering traffic based on associated forwarding equivalence classes
TWI404537B (zh) 2005-08-19 2013-08-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
TWI382019B (zh) * 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
MX2009000132A (es) * 2006-06-30 2009-01-26 Schering Corp Metodo para el uso de piperidinas sustituidas que incrementan la actividad de p53.
JPWO2008072655A1 (ja) 2006-12-14 2010-04-02 第一三共株式会社 イミダゾチアゾール誘導体
US8238361B2 (en) * 2006-12-18 2012-08-07 Telefonaktiebolaget Lm Ericsson (Publ) Scheduling and queue management with adaptive queue latency
JPWO2009151069A1 (ja) 2008-06-12 2011-11-17 第一三共株式会社 ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
US7948986B1 (en) 2009-02-02 2011-05-24 Juniper Networks, Inc. Applying services within MPLS networks
PT2467377T (pt) 2009-08-18 2017-04-04 Array Biopharma Inc Benzoazepinas substituídas como moduladores de recetores de tipo toll
PL2467380T3 (pl) 2009-08-18 2017-09-29 Ventirx Pharmaceuticals, Inc. Podstawione benzoazepiny jako modulatory receptora typu Toll
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8775352B2 (en) * 2010-03-01 2014-07-08 At&T Intellectual Property I, L.P. Methods and apparatus to model end-to-end class of service policies in networks
CN102190631B (zh) * 2010-03-10 2014-10-29 中国人民解放军63975部队 苯二氮卓化合物的制备方法
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
EP2948451B1 (en) 2013-01-22 2017-07-12 Novartis AG Substituted purinone compounds
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
AU2014272774B2 (en) 2013-05-27 2016-12-08 Novartis Ag Imidazopyrrolidinone derivatives and their use in the treatment of disease
CN105263934B (zh) 2013-05-28 2017-09-08 诺华股份有限公司 作为bet抑制剂的吡唑并‑吡咯烷‑4‑酮衍生物及其在治疗疾病中的用途
MX2015016425A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
CN105916857B (zh) 2013-11-21 2018-06-22 诺华股份有限公司 吡咯并吡咯酮衍生物及其作为bet抑制剂的用途
WO2015108136A1 (ja) * 2014-01-17 2015-07-23 キッセイ薬品工業株式会社 α－置換グリシンアミド誘導体
JP6823587B2 (ja) 2015-04-13 2021-02-03 第一三共株式会社 Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法
CN105693634B (zh) * 2016-03-17 2018-12-11 清华大学 化合物及其用途
CN115242726B (zh) * 2022-07-27 2024-03-01 阿里巴巴（中国）有限公司 队列的调度方法和装置及电子设备

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6092115A (en) * 1997-02-07 2000-07-18 Lucent Technologies Inc. Method for supporting per-connection queuing for feedback-controlled traffic
US6104700A (en) * 1997-08-29 2000-08-15 Extreme Networks Policy based quality of service
US6233245B1 (en) * 1997-12-24 2001-05-15 Nortel Networks Limited Method and apparatus for management of bandwidth in a data communication network
US6492553B1 (en) * 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6515963B1 (en) * 1999-01-27 2003-02-04 Cisco Technology, Inc. Per-flow dynamic buffer management
US6680933B1 (en) * 1999-09-23 2004-01-20 Nortel Networks Limited Telecommunications switches and methods for their operation
CN1611035A (zh) * 2001-04-13 2005-04-27 飞思卡尔半导体公司 数据流处理器中的数据流管理

Also Published As

Publication number Publication date
JP2007525457A (ja) 2007-09-06
IS8074A (is) 2005-10-14
EP1617807A4 (en) 2007-02-21
NO20055568L (no) 2006-01-20
KR20060007035A (ko) 2006-01-23
WO2004096134A3 (en) 2005-12-08
CN1809362A (zh) 2006-07-26
CO5700770A2 (es) 2006-11-30
BRPI0409641A (pt) 2006-04-25
EP1617807A2 (en) 2006-01-25
NO20055568D0 (no) 2005-11-24
US20040213264A1 (en) 2004-10-28
AU2004233833A1 (en) 2004-11-11
CA2523561A1 (en) 2004-11-11
WO2004096134A2 (en) 2004-11-11
HRP20050919A2 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
SI1585739T1 (sl) Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze
SI1678166T1 (sl) Inhibitorji proteinske kinaze
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
DE602004024375D1 (de) Carboxamidderivate
MY143698A (en) Substituted morpholine and thiomorpholine derivatives.
SE0400284D0 (sv) Novel compounds
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
MY151003A (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
MXPA05009282A (es) Derivados de anilina sustituidos.
EA200501513A1 (ru) Замещённые 1, 4 - диазепины и их применения
DE60114640D1 (en) Antithrombosemittel
TW200628153A (en) Novel compounds
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
GB0212410D0 (en) Organic compounds
AU2003281220A1 (en) N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/ or serotonin reuptake inhibitors
WO2006031929A3 (en) Thiazolopyridine kinase inhibitors

Legal Events

Date Code Title Description
FG Grant or registration